UC-MSC injection (Shandong Province Qilu Stem Cells Engineering)

UC-MSC injection is a cell therapy product developed by Shandong Province Qilu Stem Cells Engineering, utilizing mesenchymal stem cells (MSCs) harvested from human umbilical cord tissue. The therapy is designed to treat chronic wounds, specifically diabetic foot ulcers, by leveraging the innate regenerative and immunomodulatory capabilities of MSCs. Upon administration via injection, these cells secrete various growth factors and cytokines that promote angiogenesis, reduce inflammation, and accelerate the healing of damaged tissues. The product is currently involved in clinical research collaborations with hospitals in China, such as those in Xuzhou and Changhai, focusing on the treatment of diabetic foot wounds.